# SBIR Funds CellectGen Test Development

The federal Small Business Innovation Research (SBIR) program awarded CellectGen a grant to develop a saliva-based, point-of-care test for periodontal tissue destruction, with Kemp Proteins and DCNDx supporting development. The grant funds product development, not a market-ready diagnostic; the signal reports no award amount, validation results, or launch timeline. For healthcare procurement professionals and contractors, this is an early-stage diagnostic R&D development rather than an available product or near-term purchasing opportunity.

- The effort combines CellectGen’s diagnostic platform development with Kemp Proteins’ antibody capabilities and DCNDx’s lateral-flow test development.
- Healthcare companies working in point-of-care diagnostics can assess potential technical collaboration or supporting capabilities; product readiness and validation remain unreported.
- No grant amount, solicitation details, or delivery schedule are provided, so the signal does not establish a forecastable procurement value or deadline.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Grants & Funding
**Published:** October 28, 2026

### Government Entities
- Small Business Innovation Research program (SBIR)

### Vendors
- CellectGen (SBIR grant recipient and diagnostic platform developer)
- Kemp Proteins (Monoclonal antibody developer)
- DCNDx (Lateral-flow test developer)

### Key Quotes
> Our platform will help clinicians answer three critical questions: What is the level of active tissue destruction? What is the patient's risk of future disease progression? And is the current therapy working?
> — Robert Gellibolian, Chief Executive Officer of CellectGen

> Diagnostics are only as strong as the reagents behind them.
> — Mike Keefe, Chief Executive Officer of Kemp Proteins

### Sources
- [CellectGen wins SBIR grant for saliva-based periodontal test | Dealroom.co](https://app.dealroom.co/news/note/cellectgen-wins-sbir-grant-for-saliva-based-periodontal-test) - Dealroom